These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 19256578)

  • 1. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
    Angthong C; Angthong W
    J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
    Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
    Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
    Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
    Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
    N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and atypical femoral fractures: a time for reflection.
    Compston JE
    Maturitas; 2010 Jan; 65(1):3-4. PubMed ID: 19932574
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-energy femoral shaft fractures associated with alendronate use.
    Neviaser AS; Lane JM; Lenart BA; Edobor-Osula F; Lorich DG
    J Orthop Trauma; 2008; 22(5):346-50. PubMed ID: 18448990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
    Chan SS; Rosenberg ZS; Chan K; Capeci C
    AJR Am J Roentgenol; 2010 Jun; 194(6):1581-6. PubMed ID: 20489100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical fractures on long term bisphosphonates therapy.
    Hussein W; Cunningham C; Logan H; Fallon C; Murphy S
    Ir Med J; 2011; 104(10):308, 310. PubMed ID: 22256444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.
    Ng YH; Gino PD; Lingaraj K; Das De S
    Injury; 2011 Jul; 42(7):702-6. PubMed ID: 21316051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
    Lee JK
    Int J Rheum Dis; 2009 Jul; 12(2):149-54. PubMed ID: 20374333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.
    Capeci CM; Tejwani NC
    J Bone Joint Surg Am; 2009 Nov; 91(11):2556-61. PubMed ID: 19884427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
    Miller PD; McCarthy EF
    Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
    Wang K; Moaveni A; Dowrick A; Liew S
    J Orthop Surg (Hong Kong); 2011 Apr; 19(1):89-92. PubMed ID: 21519086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
    Soen S
    Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
    Cross MB; Nam D; van der Meulen MC; Bostrom MP
    J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.
    Cermak K; Shumelinsky F; Alexiou J; Gebhart MJ
    Clin Orthop Relat Res; 2010 Jul; 468(7):1991-6. PubMed ID: 20020334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.